Suria Hamza 4
4 · ANAPTYSBIO, INC · Filed Oct 28, 2021
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
Suria Hamza
DirectorPresident, CEO
Transactions
- Exercise/Conversion
Common Stock
2021-10-26$1.12/sh+15,993$17,912→ 83,629 total - Sale
Common Stock
2021-10-26$30.00/sh−15,993$479,790→ 67,636 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-10-26−15,993→ 73,291 totalExercise: $1.12Exp: 2022-01-31→ Common Stock (15,993 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022.
- [F3]In addition to the remaining options to purchase 73,291 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.